Search results
Ozempic-Maker Novo Nordisk Sues Pharmacies And Weight Loss Clinics For Allegedly Selling Impure...
Forbes· 5 days agoNovo Nordisk has filed nine lawsuits against medical spas, wellness clinics and pharmacies for...
Wegovy maker Novo Nordisk sues nine spas, clinics and pharmacies over copycat drugs
Reuters via Yahoo News· 5 days ago(Reuters) -Novo Nordisk said on Thursday it had sued nine more medical spas, wellness clinics and...
Popular diet and diabetes drugs in short supply as demand surges
AOL· 13 hours agoWeight loss drugs like Ozempic, Wegovy and Zepbound continue to be in short supply. The weekly...
Psychoactive drugs are having a moment. The FDA will soon weigh in
The State· 1 day agoPsychoactive drugs are having a moment. Investors are piling into the nascent field, and a host of medications based on MDMA, LSD, psychedelic mushrooms, ketamine, the South American plant mixture ...
Revolutionary new drug for sleep apnea could put an end to CPAP machines
NY Post via Yahoo News· 4 days agoNew research suggests a pill may soon replace CPAPs as the treatment of choice for sleep apnea. A...
What Happened After I Stopped Taking a Weight-Loss Drug
The Wall Street Journal· 5 days agoFour months ago, I wrote about losing 40 pounds on Mounjaro and wondered how I would do without the ...
Gangs mix another potent sedative into U.S. street drugs causing 'mass overdoses'
WUSF 89.7· 6 days agoPublic health officials say Mexican cartels and drug gangs inside the U.S. are mixing a dangerous...
The race for a weight loss pill heats up as a Novo Nordisk competitor releases new trial results
Quartz· 21 hours agoIt’s the latest development in the race among several pharmaceutical companies to introduce new...
Judge Lets More Than 70,000 Zantac Lawsuits Go Forward
Insurance Journal· 9 hours agoA Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go...
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says
Reuters· 1 day agoVaccine makers should consider targeting one of the currently dominant JN.1 variants and...